GIM-122

GIM-122 (GIM122) is a humanised IgG1 kappa dual-functioning monoclonal antibody from Georgiamune. A dual-functioning antibody that the company says overcomes cancer-mediated immune suppression and at the same time stimulates activated T cells; targets not disclosed. Its furthest stage is phase 1, for advanced solid malignancies. ClinicalTrials.gov registers it in one study linked below. FDA IND clearance August 2023; phase 1/2 recruiting per registry (NCT06028074). Whether it works in people has not been established unless a trial below reports it.